chr7:140453154:T>C Detail (hg19) (BRAF)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr7:140,453,154-140,453,154 |
hg38 | chr7:140,753,354-140,753,354 View the variant detail on this assembly version. |
HGVS
Type | Transcript | Protein |
---|---|---|
RefSeq | NM_004333.4:c.1901A>G | NP_004324.2:p.Asp634Gly |
Ensemble | ENST00000288602.11:c.1901A>G | ENST00000288602.11:p.Asp634Gly |
ENST00000496384.7:c.1781A>G | ENST00000496384.7:p.Asp594Gly |
Summary
MGeND
Clinical significance |
![]() |
Variant entry | 43 |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
ClinVar
Clinical Significance | Conflicting classifications of pathogenicity |
Review star | ![]() |
Show details |
Disease area statistics
MGeND
Clinical significance | Last evaluated | Condition | Origin | Submission ID | Submitter | Institute | Citation | Comment | Image |
---|---|---|---|---|---|---|---|---|---|
![]() |
pyloric antrum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
descending colon |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
malignant neoplasm of rectum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
bronchus or lung, unspecified |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
fundus of stomach |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
caecum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
ascending colon |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
descending colon |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
sigmoid colon |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
colon, unspecified |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
malignant neoplasm of rectum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
fundus of stomach |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
small intestine, unspecified |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
caecum |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
ascending colon |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
descending colon |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
sigmoid colon |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
colon, unspecified |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
malignant neoplasm of rectum |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
bronchus or lung, unspecified |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan |
ClinVar
Clinical significance | Last evaluated | Review status | Condition | Origin | Links |
---|---|---|---|---|---|
![]() |
2003-11-17 | no assertion criteria provided | non-Hodgkin lymphoma |
![]() |
Detail |
![]() |
2012-06-11 | criteria provided, single submitter | Non-small cell lung carcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | B-cell chronic lymphocytic leukemia |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Malignant melanoma of skin |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | lung adenocarcinoma |
![]() |
Detail |
![]() |
2015-07-14 | no assertion criteria provided | melanoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Adrenal cortex carcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Squamous cell carcinoma of the head and neck |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided |
![]() |
Detail | |
![]() |
2016-05-31 | no assertion criteria provided | multiple myeloma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Neoplasm of brain |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Neoplasm of the large intestine |
![]() |
Detail |
![]() |
2021-08-03 | criteria provided, single submitter | RASopathy |
![]() |
Detail |
CIViC
Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
colorectal cancer | B |
![]() |
![]() |
Poor Outcome | Somatic | 1 | 27404270 | Detail | |
colorectal cancer | B |
![]() |
![]() |
Poor Outcome | Somatic | 2 | 27404270 | Detail | |
colorectal cancer | Panitumumab,Cetuximab | C |
![]() |
![]() |
Resistance | Somatic | 1 | 27404270 | Detail |
colorectal cancer | Cetuximab,Irinotecan | C |
![]() |
![]() |
Resistance | Somatic | 3 | 26989027 | Detail |
skin melanoma | Sorafenib | D |
![]() |
![]() |
Sensitivity/Response | Somatic | 3 | 18794803 | Detail |
skin melanoma | U0126 | D |
![]() |
![]() |
Resistance | 3 | 18794803 | Detail | |
Solid Tumor | Vemurafenib | D |
![]() |
![]() |
Sensitivity/Response | Somatic | 3 | 28783719 | Detail |
cancer | Trametinib | D |
![]() |
![]() |
Sensitivity/Response | Somatic | 2 | 28783719 | Detail |
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.242 | Lymphoma, Non-Hodgkin | NA | CLINVAR | Detail | |
0.001 | Melanocytic nevus of skin | The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus ha... | BeFree | 15009715 | Detail |
0.004 | Nevus | The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus ha... | BeFree | 15009715 | Detail |
0.001 | Benign melanocytic nevus | The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus ha... | BeFree | 15009715 | Detail |
0.002 | follicular adenoma | BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along wi... | BeFree | 19269016 | Detail |
0.120 | B-Cell Lymphomas | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... | BeFree | 22575864 | Detail |
<0.001 | diffuse large B-cell lymphoma | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... | BeFree | 22575864 | Detail |
0.002 | Thyroid Gland Follicular Adenoma | BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along wi... | BeFree | 19269016 | Detail |
0.015 | Malignant neoplasm of lung | The three most common BRAF mutations in lung cancers accounted for only 41% of t... | BeFree | 26386083 | Detail |
0.125 | Carcinoma of lung | The three most common BRAF mutations in lung cancers accounted for only 41% of t... | BeFree | 26386083 | Detail |
<0.001 | diffuse large B-cell lymphoma | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... | BeFree | 22575864 | Detail |
0.001 | B-Cell Lymphomas | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... | BeFree | 22575864 | Detail |
0.131 | Non-small cell lung carcinoma | NA | CLINVAR | Detail | |
0.002 | Papillary microcarcinoma | BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along wi... | BeFree | 19269016 | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 pati... | CIViC Evidence | Detail |
In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589... | CIViC Evidence | Detail |
Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and... | CIViC Evidence | Detail |
In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patien... | CIViC Evidence | Detail |
In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations ... | CIViC Evidence | Detail |
In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations ... | CIViC Evidence | Detail |
RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express cla... | CIViC Evidence | Detail |
In a BRAF-mutation inducible model in the NIH3T3 cell line, class 3 BRAF mutations (G466V, G466E, D5... | CIViC Evidence | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Non-Hodgkin lymphoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Non-small cell lung carcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND B-cell chronic lymphocytic leukemia | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Malignant melanoma of skin | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Lung adenocarcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Melanoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Adrenal cortex carcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Squamous cell carcinoma of the head and neck | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Transitional cell carcinoma of the bladder | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Multiple myeloma | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Neoplasm of brain | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND Neoplasm of the large intestine | ClinVar | Detail |
NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) AND RASopathy | ClinVar | Detail |
NA | DisGeNET | Detail |
The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus had a novel A1781G (D5... | DisGeNET | Detail |
The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus had a novel A1781G (D5... | DisGeNET | Detail |
The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus had a novel A1781G (D5... | DisGeNET | Detail |
BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along with p.G606G silent ch... | DisGeNET | Detail |
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... | DisGeNET | Detail |
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... | DisGeNET | Detail |
BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along with p.G606G silent ch... | DisGeNET | Detail |
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... | DisGeNET | Detail |
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... | DisGeNET | Detail |
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... | DisGeNET | Detail |
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... | DisGeNET | Detail |
NA | DisGeNET | Detail |
BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along with p.G606G silent ch... | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs121913338 dbSNP
- Genome
- hg19
- Position
- chr7:140,453,154-140,453,154
- Variant Type
- snv
- Reference Allele
- T
- Alternative Allele
- C
- Variant (CIViC) (CIViC Variant)
- D594G
- Transcript 1 (CIViC Variant)
- ENST00000288602.6
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/611
- Summary (CIViC Variant)
- This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.
Genome browser